文献速递儿童呼吸儿童感染

尘螨皮下免疫治疗儿童呼吸道过敏全身不良反应危险因素分析

[Risk factors analysis of systemic adverse reactions to subcutaneous immunotherapy for dust mites in children with respiratory allergic diseases].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2026-01-01

多因素分析显示既往特应性皮炎史、既往反复局部不良反应史、近1周呼吸道感染和集群治疗是全身不良反应的独立危险因素。

要点

  • 尘螨SCIT患儿全身不良反应发生率为22.2%,以Ⅰ级为主,无Ⅳ级发生。
  • 既往特应性皮炎史、反复局部不良反应史、近1周呼吸道感染、集群治疗为独立危险因素。
  • 对上述危险因素患儿行SCIT时需更警惕全身不良反应。

核心结论

  • 尘螨SCIT在儿童中安全性良好,但既往特应性皮炎史、反复局部不良反应史、近1周呼吸道感染及集群治疗者需警惕全身不良反应。

研究设计与样本

  • 前瞻性队列研究,纳入2023年3月至2024年12月深圳市儿童医院呼吸科531例接受尘螨SCIT的呼吸道过敏患儿。
  • 收集年龄、性别、合并症、过敏情况、皮肤点刺试验、血清尘螨特异性IgE及肺功能等资料,记录全身不良反应并分级。

主要发现

  • 全身不良反应中Ⅰ级156例次(63.2%)、Ⅱ级76例次(30.8%)、Ⅲ级15例次(6.1%),无Ⅳ级发生。
  • SR组未规范药物治疗、屋尘螨和粉尘螨皮肤点刺≥3+及特异性IgE≥17.5 kU/L比例均高于非SR组(均P<0.05)。

关键数值与推荐

  • 多因素Logistic回归显示既往特应性皮炎史OR=2.20(95%CI 1.34~3.68)、既往反复局部不良反应史OR=2.08(95%CI 1.11~3.92)、近1周呼吸道感染OR=1.85(95%CI 1.07~3.19)、集群治疗OR=1.76(95%CI 1.13~2.76)均为独立危险因素(均P<0.05)。

临床怎么用

  • 对既往有特应性皮炎史、反复局部不良反应史、近1周呼吸道感染或采用集群治疗的患儿,SCIT期间应加强监测和警惕全身不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the risk factors for systemic reaction (SR) in children with allergic rhinitis (AR) and (or) allergic asthma (AA) undergoing house dust mite subcutaneous immunotherapy (SCIT). Methods: A prospective cohort study was conducted involving 531 children at the Department of Respiratory Medicine of Shenzhen Children's Hospital between March 2023 and December 2024, who received house dust mite SCIT. Data collected included age, gender, comorbidities, allergy profile, along with results of skin prick tests, serum house dust mite-specific IgE, and pulmonary function tests. Information regarding the clinical manifestations and severity grading of SCIT-induced SR was recorded. Based on the occurrence of SR during SCIT, the children were divided into an SR group and a non-SR group. The chi-square test or Mann-Whitney test was used to compare general conditions and clinical characteristics between the two groups, and Logistic regression was used to analyze the risk factors for SR. Results: A total of 531 children were enrolled, receiving 11 616 injections of house dust mite SCIT. Among them, 368 cases were male and 163 cases were female, with an age at presentation of 8.2 (5.0, 10.0) years. There were 281 cases (52.9%) children with AR alone and 250 cases (47.1%) with both AR and AA. SR occurred in 118 cases, while 413 cases did not experience SR. SR occurred in 118 children (22.2%), accounting for 247 episodes (2.1%) injection-related events. Among these events, 156 episodes (63.2%) were Grade Ⅰ SR, 76 episodes (30.8%) were Grade Ⅱ SR, and 15 episodes (6.1%) were Grade Ⅲ SR. No Grade Ⅳ SR occurred. In the SR group, the proportions of those receiving non-standardized drug treatment, those with a skin prick test reaction of ≥3+ to dermatophagoides pteronyssinus and dermatophagoides farinae, and those with specific IgE levels of ≥17.5 kU/L to dermatophagoides pteronyssinus and dermatophagoides farinae were higher than those in the non-SR group (all P<0.05). Multivariate Logistic regression analysis identified the following as independent risk factors for SR (all P<0.05): a history of atopic dermatitis (OR=2.20, 95%CI 1.34-3.68), a history of repeated local adverse reaction (LR) (OR=2.08, 95%CI 1.11-3.92), respiratory infection within the past week (OR=1.85, 95%CI 1.07-3.19), and cluster therapy (OR=1.76,95%CI 1.13-2.76). Conclusions: House dust mite SCIT demonstrates a favorable safety profile in children. Increased vigilance for SR is warranted during SCIT for children with a history of atopic dermatitis, a history of recurrent LR, cluster therapy, or a recent respiratory infection within the past week. 目的: 分析尘螨皮下特异性免疫治疗(SCIT)儿童过敏性鼻炎(AR)和(或)过敏性哮喘(AA)发生全身不良反应(SR)的危险因素。 方法: 前瞻性队列研究,纳入2023年3月至2024年12月在深圳市儿童医院呼吸科接受尘螨SCIT的531例呼吸道过敏患儿,收集年龄、性别、合并症、过敏情况等资料。采集尘螨特异性IgE、肺功能等检查结果,记录SCIT致SR的信息。根据患儿SCIT过程中SR的发生情况,分为SR组与非SR组,采用χ2检验或Mann-Whitney秩和检验比较两组患儿的一般情况及临床特征,使用Logistic回归对发生SR的危险因素进行分析。 结果: 531例患儿中,男368例、女163例,就诊年龄8.2(5.0,10.0)岁。281例(52.9%)为AR患儿,250例(47.1%)为AR合并AA患儿,SR组118例、非SR组413例。531例患儿共接受尘螨SCIT注射11 616次,有118例(22.2%)患儿发生247例次(2.1%)SR,其中Ⅰ级SR 156例次(63.2%)、Ⅱ级SR 76例次(30.8%)、Ⅲ级SR 15例次(6.1%),无Ⅳ级SR发生。SR组未规范药物治疗、屋尘螨、粉尘螨皮肤点刺≥3+和屋尘螨、粉尘螨特异性IgE≥17.5 kU/L比例均高于非SR组(均 P<0.05)。多因素Logistic回归分析显示,既往特应性皮炎(AD)史(OR=2.20,95%CI 1.34~3.68)、既往反复局部不良反应(LR)史(OR=2.08,95%CI 1.11~3.92)、近1周呼吸道感染(OR=1.85,95%CI 1.07~3.19)、集群治疗(OR=1.76,95%CI 1.13~2.76)均是发生SR的独立危险因素(均P<0.05)。 结论: 对于既往AD史、既往反复LR发生史、近1周呼吸道感染史、集群治疗的患儿在SCIT时更需警惕SR的发生。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Fan TT, Zhuang SJ, Lai RL, et al. [Risk factors analysis of systemic adverse reactions to subcutaneous immunotherapy for dust mites in children with respiratory allergic diseases]. Zhonghua Er Ke Za Zhi. 2026. PMID: 42135238. doi:10.3760/cma.j.cn112140-20251223-01133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。